Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.12.2023 | Case report

Furmonertinib

Various toxicities: 5 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Qi R, et al. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study. Lung Cancer 184: Oct 2023. Available from: URL: https://www.elsevier.com/locate/lungcan Qi R, et al. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study. Lung Cancer 184: Oct 2023. Available from: URL: https://​www.​elsevier.​com/​locate/​lungcan
Metadaten
Titel
Furmonertinib
Various toxicities: 5 case reports
Publikationsdatum
01.12.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51495-y

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Nivolumab

Case report

Triptorelin

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Multiple drugs